Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma
Y.N. Vashisht Gopal(The University of Texas MD Anderson Cancer Center), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Bradley M. Broom(The University of Texas MD Anderson Cancer Center), Prahlad T. Ram(The University of Texas MD Anderson Cancer Center), Cristiano Gonçalves Pereira(Instituto Butantan), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Paul D. Smith(Epworth Hospital), Dennie T. Frederick(Broad Institute), Kakajan Komurov(University of Cincinnati), Jiexin Zhang(The University of Texas MD Anderson Cancer Center), Helen Rizos(Macquarie University), Georgina V. Long(The University of Sydney), Zachary A. Cooper(AstraZeneca (Singapore)), Richard A. Scolyer(The University of Sydney), Gulietta M. Pupo(Westmead Hospital), Guo Chen(Jinan University), Vasudha Sehgal(Moderna Therapeutics (United States)), Lalit R. Patel(The University of Texas MD Anderson Cancer Center), Wanleng Deng(The University of Texas MD Anderson Cancer Center), Gordon B. Mills(The University of Texas MD Anderson Cancer Center)
Cited by 205
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k